Clinical Events Associated With Cumulative Corticosteroid Use In Patients With Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

236Background: Corticosteroids (CSs) are used in the treatment of castration-resistant prostate cancer (CRPC) to manage adverse events and tumor-related symptoms. This study evaluated the impact of cumulative CS use on the risk of developing specific clinical events in men with CRPC. Methods: Adult chemotherapy-naive patients who initiated a CRPC treatment following surgical or medical castration were identified from the MarketScan database (2007–2016). Patients were grouped into 4 cohorts based on their cumulative CS dose since 1 year before initiating their CRPC treatment: no use (0 g); low use ( 2.0 g). Time-dependent Cox proportional hazards models adjusting for baseline characteristics were used to evaluate the association between CS use and the risk of events (fracture, infection, endocrine disorders, acute cardiovascular [CV] events, peptic ulcer, and mental health conditions), with no CS use as the reference group. Results: This study included 942...